Σύγκριση μεθόδων

	Δείκτης Βλάβης Αγγειίτιδας (VDI)	Δείκτης Δραστηριότητας Νόσου 28 Αρθρώσεων (DAS28)	Δείκτης Δραστηριότητας Νόσου Συστηματικού Ερυθηματώδους Λύκου 2000 (SLEDAI-2K)
Πεδίο	Ρευματολογία	Ρευματολογία	Ρευματολογία
Οικογένεια	Process / pipeline	Process / pipeline	Process / pipeline
Έτος προέλευσης	2003	1995	2002
Δημιουργός	Exley et al.	Prevoo et al.	Gladman et al.
Τύπος	Clinician-rated	Clinician-rated	Clinician-rated
Θεμελιώδης πηγή	Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Pusey CD, Savage CO. Development and initial validation of the Vasculitis Damage Index (VDI) for systemic vasculitis. Arthritis & Rheumatism. 2003;48(7):2146-2157.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
Εναλλακτικές ονομασίες	VDI, Vasculitis Permanent Organ Damage Score	DAS28, DAS28-CRP, DAS28-ESR	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
Συναφείς	4	3	3
Σύνοψη	The VDI is a clinician-assessed measure of permanent organ damage in patients with systemic vasculitis, including ANCA-associated vasculitis (AAV), polyarteritis nodosa, and other necrotising vasculitides. Introduced by Exley et al. (2003), VDI captures cumulative irreversible damage across organ systems, complementing disease activity measures (such as the Birmingham Vasculitis Activity Score). Systemic vasculitis is characterised by inflammation of blood vessel walls, leading to ischaemia and permanent tissue damage. VDI acknowledges that damage accrues over time and is largely irreversible, making it a prognostically important measure distinct from transient inflammatory activity.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.